The use of probiotic bacteria in the manufacture of a composition for administration to a pregnant woman in at least the third trimester of pregnancy for the prevention of gestational diabetes, in which a mixture of probiotic bacteria of lactic acid and Bifidobacteria is used , and where the lactic acid probiotic bacteria are Lactobacillus rhamnosus CGMCC 1.3724 and the probiotic Bifidobacterium is the Bifidobacterium lactis CNCMI-3446.
展开▼